GLYCOPYRROLATE MSDS PDF

Home  /   GLYCOPYRROLATE MSDS PDF

SAFETY DATA SHEET. PRODUCT: Glycopyrrolate Injection USP. Section 1: PRODUCT AND COMPANY INFORMATION. 54/1, Boodhihal village,. Nelamangala. Glycopyrrolate. 1-Methylpyrrolidyl alpha-phenylcyclopentaneglycolate methobromide;. Glycopyrrolate bromide; Glycopyrronium bromide. Glycopyrronium (as the bromide salt glycopyrrolate) is a synthetic anticholinergic agent In October , glycopyrrolate was approved by the FDA for use as a FDA label. Download ( KB). MSDS. Download ( KB).

Author: Fenrinos Zululrajas
Country: Bahrain
Language: English (Spanish)
Genre: Spiritual
Published (Last): 17 January 2015
Pages: 236
PDF File Size: 18.60 Mb
ePub File Size: 14.76 Mb
ISBN: 985-8-63742-729-4
Downloads: 79391
Price: Free* [*Free Regsitration Required]
Uploader: Dar

The serum concentration of Benzthiazide can be increased when it is combined with Glycopyrronium.

Phenserine The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Phenserine. Phenglutarimide The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Glycopyrronium.

Metamfetamine The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Metamfetamine. Magnesium Trisilicate The therapeutic efficacy of Magnesium Trisilicate can be decreased when used in combination with Glycopyrronium. Plantago seed The therapeutic efficacy of Plantago seed can be decreased when used in combination with Glycopyrronium.

Trichlormethiazide The serum concentration of Trichlormethiazide can be increased when it is combined with Glycopyrronium. Dobutamine The risk or severity of Tachycardia can be increased when Dobutamine is combined with Glycopyrronium.

Cannabidiol The risk or severity of Tachycardia and drowsiness can be increased when Glycopyrronium is combined with Cannabidiol. Tretoquinol The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Tretoquinol.

Surinabant The risk or severity of Tachycardia and drowsiness can be increased when Glycopyrronium is combined with Surinabant. The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Cirazoline. The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Ephedrine. Mianserin Mianserin may increase the anticholinergic activities of Glycopyrronium.

The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Glycopyrronium. The risk or severity of adverse effects can be increased when Prifinium is combined with Glycopyrronium.

  ABB MINIFIX 210 PDF

The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Dihydrostreptomycin. The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Glycopyrronium. Quinidine The risk or severity of adverse effects can be increased when Quinidine is combined with Glycopyrronium.

Framycetin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Framycetin.

Glycopyrronium

The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Dopexamine. Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with Glycopyrronium. Diphemanil Methylsulfate The risk or severity of adverse effects can be increased when Diphemanil Methylsulfate is combined with Glycopyrronium. Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Glycopyrronium.

The risk or severity of adverse effects can be increased when Ipratropium is combined with Glycopyrronium. The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Glycopyrronium. Magnesium oxide The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Glycopyrronium. The therapeutic efficacy of Potassium nitrate can be decreased when used in combination with Glycopyrronium.

The therapeutic efficacy of Docusate can be decreased when used in combination with Glycopyrronium. The risk or severity of Tachycardia can be increased when Duloxetine is combined with Glycopyrronium. Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Glycopyrronium. Magnesium peroxide The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Glycopyrronium.

Naltrexone The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Naltrexone. The risk or severity of adverse effects can be increased when Fenpiverinium is combined with Glycopyrronium.

Nabiximols The risk or severity of Tachycardia and drowsiness can be increased when Glycopyrronium is combined with Nabiximols. The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Octopamine. The risk or severity of adverse effects can be increased when Buclizine is combined with Glycopyrronium.

  INSTITUTIONAL REASON THE JURISPRUDENCE OF ROBERT ALEXY PDF

Eluxadoline The risk or severity of constipation can be increased when Glycopyrronium is combined with Eluxadoline.

Glycopyrronium – DrugBank

Salbutamol The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Salbutamol. Levomilnacipran The risk or severity of Tachycardia glycopyrgolate be increased when Glycopyrronium is combined with Levomilnacipran.

Atenolol The bioavailability of Glyckpyrrolate can be increased when combined with Glycopyrronium. Ractopamine The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Ractopamine. The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Dichlorvos. The risk or severity of adverse effects can be increased when Pirenzepine is combined with Glycopyrronium. Plazomicin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Plazomicin.

Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Glycopyrronium. Methadyl acetate The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Methadyl acetate. Epinephrine The risk or severity of Tachycardia can be increased when Epinephrine is combined with Glycopyrronium. Butabarbital Butabarbital may increase the anticholinergic activities of Glycopyrronium.

General Function Phosphatidylinositol phospholipase c activity Specific Function The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the Remifentanil The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Remifentanil.

Opium The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Opium. Hence it can be used for treating ulcers in the stomach and small intestine, in combination with other medications.

The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Lisdexamfetamine.